Tissue Engineered Transcatheter Pulmonary Valved Stent Implantation: Current State and Future Prospect

Abstract

Patients with the complex congenital heart disease (CHD) are usually associated with right ventricular outflow tract dysfunction and typically require multiple surgical interventions during their lives to relieve the right ventricular outflow tract abnormality. Transcatheter pulmonary valve replacement was used as a non-surgical, less invasive alternative treatment for right ventricular outflow tract dysfunction and has been rapidly developing over the past years. Despite the current favorable results of transcatheter pulmonary valve replacement, many patients eligible for pulmonary valve replacement are still not candidates for transcatheter pulmonary valve replacement. Therefore, one of the significant future challenges is to expand transcatheter pulmonary valve replacement to a broader patient population. This review describes the limitations and problems of existing techniques and focuses on decellularized tissue engineering for pulmonary valve stenting.

Migration and Thrombosis of Injectable Pulmonary Valve

“…Approximately 20% of newborns with congenital heart disesase have anatomic dismorphism of the pulmonary valve or right ventricular outflow tract (1). Tetralogy of Fallot, common arterial trunk, or pulmonary atresia are the most common congenital heart diseases which require pulmonary valve repair or intervention.…”